Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21893827 | 0.78 | SCN5A (0.50) | SCN5AMAPK14CYP1A2PIM1SRC | |
| SCHEMBL22712660 | 0.78 | SCN5A (0.50) | SCN5AMAPK14CYP1A2 | |
| SCHEMBL17681362 | 0.74 | FGFR1 (0.58) | SCN5AMAPK14PIM1RETFGFR1 | |
| SCHEMBL24656674 | 0.74 | SCN5A (0.50) | SCN5AMAPK14CYP1A2 | |
| SCHEMBL20986006 | 0.73 | SCN5A (0.36) | SCN5AMAPK14CYP1A2 | |
| SCHEMBL21818561 | 0.73 | MAPK14 (0.46) | SCN5AMAPK14CYP1A2 | |
| SCHEMBL16686975 | 0.68 | MAPK14 (0.47) | SCN5AMAPK14PIM1RETFGFR1 | |
| SCHEMBL20190440 | 0.66 | CYP1A2 (0.43) | SCN5AMAPK14CYP1A2 | |
| SCHEMBL16687070 | 0.64 | POLB (0.36) | SCN5AMAPK14PIM1RETFGFR1 | |
| SCHEMBL16268292 | 0.64 | BRD4 (0.39) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20240043450-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-08 | — | — | US | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | SCN5A 2180/4885MAPK14 3455/4885CYP1A2 1119/4885 |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | SCN5A 490/4885MAPK14 2975/4885CYP1A2 573/4885 |
| US-20240043450-A1 | NEW COMPOUND | NLRP3, NLRP1, PYCARD | SCN5A 1964/4885MAPK14 3137/4885CYP1A2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.